MarketBeat on MSN

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...
Pharmaceutical Technology on MSN

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...
STAT

BridgeBio wins FDA approval for heart disease drug

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The Food and Drug ...
Seeking Alpha

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

BridgeBio remains a compelling Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics following Pfizer’s patent settlements. Attruby’s peak annual sales are conservatively ...
Nasdaq

BridgeBio Pharma Reports Significant Launch Progress for Attruby™ Following FDA Approval and EU Marketing Authorization

1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...